Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
- 23 June 2000
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 27 (7) , 766-777
- https://doi.org/10.1007/s002590000276